Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.
Infectious disease-focused Accelerate Diagnostics Inc. netted $74.6mm through the upsized follow-on offering of 2.75mm common shares priced at $28.85. The company originally planned to sell 2.5mm shares. (May) Investment Banks/Advisors: BTIG LLC; JP Morgan & Co.; Piper Jaffray & Co.; William Blair & Co.
Aytu BioScience Inc. acquired private women's sexual health company Nuelle Inc. (consumer device to stimulate female sexual arousal) for up to $32.7mm, exchanging 2.5mm of its common shares...
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
